Harvard Bioscience (HBIO) Proxy Filing summary
Event summary combining transcript, slides, and related documents.
Proxy Filing summary
30 Jan, 2026Executive summary
Special Meeting scheduled for March 6, 2026, to vote on a reverse stock split and potential adjournment to solicit more proxies if needed.
Reverse stock split proposed at a ratio between 1-for-5 and 1-for-15 to regain Nasdaq compliance.
Board recommends voting in favor of both proposals to maintain Nasdaq listing and flexibility.
If approved, the Board may implement the split within six months or abandon it if not in the best interest of shareholders.
Proxy materials and voting instructions provided for online, phone, and mail participation.
Voting matters and shareholder proposals
Proposal 1: Approve amendment for reverse stock split at a ratio of 1-for-5 to 1-for-15.
Proposal 2: Authorize adjournment of the meeting to solicit additional proxies if Proposal 1 lacks sufficient votes.
Majority of votes cast required for approval; broker non-votes and abstentions have no impact.
Board recommends voting "FOR" both proposals.
Stockholder proposals for the 2026 annual meeting must comply with SEC and bylaw deadlines.
Board of directors and corporate governance
Board retains discretion to implement or abandon the reverse stock split within six months of approval.
No current arrangements for additional share issuance post-split.
Board believes higher share price may attract institutional investors and facilitate financing.
Latest events from Harvard Bioscience
- 2025 restructuring and margin gains set the stage for 2026 growth from new product innovation.HBIO
Q4 202512 Mar 2026 - Reverse stock split and adjournment proposals passed with over 97% approval.HBIO
EGM 20266 Mar 2026 - Q2 2024 revenue fell nearly 20% with net loss widening, prompting reduced full-year guidance.HBIO
Q2 20242 Feb 2026 - Growth driven by new organoid and bioproduction systems, with APAC recovery boosting outlook.HBIO
Jefferies Global Healthcare Conference1 Feb 2026 - Up to 9.5 million shares registered for resale, with no direct proceeds to the company.HBIO
Registration Filing30 Jan 2026 - Approval sought for a reverse stock split to maintain Nasdaq listing and shareholder value.HBIO
Proxy Filing20 Jan 2026 - New product launches and bioproduction expansion set the stage for double-digit growth.HBIO
Sidoti September Small-Cap Virtual Conference20 Jan 2026 - Revenue and margins declined, but cost cuts and new products support cautious Q4 optimism.HBIO
Q3 202416 Jan 2026 - Organoid and bioproduction innovations drive double-digit growth and recurring revenues.HBIO
Sidoti Micro-Cap Virtual Conference9 Jan 2026